Patent classifications
A61K47/16
LIGHT-CONTROLLABLE SELF-ASSEMBLED COMPLEX AND NANOSYSTEM INCLUDING THE SAME
Discloses is a technology of collecting a biological sample, delivering a substance into a living body, and regulating macrophage adhesion and polarization, by controlling a self-assembled complex and a nanosystem including the same by irradiation with light.
LIGHT-CONTROLLABLE SELF-ASSEMBLED COMPLEX AND NANOSYSTEM INCLUDING THE SAME
Discloses is a technology of collecting a biological sample, delivering a substance into a living body, and regulating macrophage adhesion and polarization, by controlling a self-assembled complex and a nanosystem including the same by irradiation with light.
Solid oral pharmaceutical compositions for isoxazoline compounds
A solid oral pharmaceutical composition for delivery of a pharmaceutically acceptable active ingredient to an animal where the composition comprises an isoxazoline compound, a solvent and an excipient, a process for the manufacture of such solid oral pharmaceutical composition and a method of controlling a parasite infection administering such solid oral pharmaceutical composition.
Solid oral pharmaceutical compositions for isoxazoline compounds
A solid oral pharmaceutical composition for delivery of a pharmaceutically acceptable active ingredient to an animal where the composition comprises an isoxazoline compound, a solvent and an excipient, a process for the manufacture of such solid oral pharmaceutical composition and a method of controlling a parasite infection administering such solid oral pharmaceutical composition.
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
Compounds are provided having the following structure:
##STR00001##
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.3, L.sup.1, L.sup.2, G.sup.1, G.sup.2 and G.sup.3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
DRUG DELIVERY SYSTEM USING SOLUTION
The present invention provides a means excellent in efficiency of introduction of a nucleic acid, a protein, a complex thereof, or the like into cells, in particular a method using a solution for transduction. In the method for transducing a molecule(s) of interest into a cell according to the present invention, comprising a step of contacting the cell with the molecule(s) of interest and a solution for transduction according to the present invention, the solution for transduction contains: at least one of the following (A1) to (A5); and (B) a salt: (A1) a compound represented by formula (I) excluding a predetermined compound, or a salt thereof; (A2) a compound represented by formula (II), or a salt thereof; (A3) a nucleic-acid base or the like, or a salt thereof; (A4) a compound represented by formula (III), or a salt thereof, excluding malic acid; and (A5) at least one selected from the group consisting of creatinine, hydroxyproline, 1,3-butanediol, trientine, D-cellobiose, 1,3-dimethylurea, pantolactone and trimethadione, or a salt thereof.
##STR00001##
DRUG DELIVERY SYSTEM USING SOLUTION
The present invention provides a means excellent in efficiency of introduction of a nucleic acid, a protein, a complex thereof, or the like into cells, in particular a method using a solution for transduction. In the method for transducing a molecule(s) of interest into a cell according to the present invention, comprising a step of contacting the cell with the molecule(s) of interest and a solution for transduction according to the present invention, the solution for transduction contains: at least one of the following (A1) to (A5); and (B) a salt: (A1) a compound represented by formula (I) excluding a predetermined compound, or a salt thereof; (A2) a compound represented by formula (II), or a salt thereof; (A3) a nucleic-acid base or the like, or a salt thereof; (A4) a compound represented by formula (III), or a salt thereof, excluding malic acid; and (A5) at least one selected from the group consisting of creatinine, hydroxyproline, 1,3-butanediol, trientine, D-cellobiose, 1,3-dimethylurea, pantolactone and trimethadione, or a salt thereof.
##STR00001##
NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION
The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA suitable for use in treatment and/or prophylaxis of an infection with yellow fewer vims (YFV) or a disorder related to such an infection. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial RNA, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial RNA, compositions and vaccines.
HYPERTONIC ANTIMICROBIAL THERAPEUTIC COMPOSITIONS
Therapeutic compositions, primarily for topical application, and methods of making and using the composition. Pharmaceutical compositions formulated for specific forms of administration are also provided.
HYPERTONIC ANTIMICROBIAL THERAPEUTIC COMPOSITIONS
Therapeutic compositions, primarily for topical application, and methods of making and using the composition. Pharmaceutical compositions formulated for specific forms of administration are also provided.